Myomo (MYO) Moat Score: 5/10 (As of Jul. 01, 2026)


MYO Myomo Inc MYO
55 GF Score
Price $1.04
GF Value $3.13
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myomo Moat Score?

Myomo MYO -6.31% 55 Moat Score is 5 as of Jul. 01, 2026. GuruFocus rates MYO with a GF Score™ of 55/100 and a GF Value™ of $3.13 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Myomo ranks better than 91.25% on this metric.

Myomo has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Myomo has Narrow Moat: Myomo Inc has a solid narrow moat due to its proprietary technology in medical devices and moderate customer loyalty. The company benefits from some pricing power and innovation capabilities but faces competition and lacks significant regulatory barriers or network effects.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Myomo might have Narrow Moat - Solid narrow moat.

Myomo  (AMEX:MYO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Myomo Moat Score Related Terms

MYO vs FOFA, ELUT, PAVM: Moat Score Comparison

For the Medical Devices subindustry, Myomo's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myomo Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Myomo's Moat Score distribution charts can be found below:

* The bar in red indicates where Myomo's Moat Score falls into.


MYO
55GF Score
Myomo Inc MYO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Myomo (MYO) has a Moat Score of 5 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Myomo ranks #74 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is Myomo's Moat Score too high?
Myomo's current Moat Score is 5. Based on the distribution chart, Myomo ranks #74 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Myomo has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myomo's Moat Score compare to FOFA and ELUT?
According to the Medical Devices & Instruments industry distribution chart, Myomo ranks #74 out of 846 companies for Moat Score. This places Myomo in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Myomo's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myomo stock overvalued right now?
Based on GuruFocus' analysis, Myomo (MYO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.13, compared to a current price of $1.04 — trading 66.8% below its estimated fair value. The current Moat Score is 5. Myomo's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Myomo (MYO), the current Moat Score is 5 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myomo (MYO) Overvalued in 2026?

Based on GuruFocus' analysis, Myomo stock appears to be undervalued. The current stock price of $1.04 is trading 66.8% below its estimated GF Value™ of $3.13. GuruFocus considers Myomo to be Possible Value Trap.

Key valuation signals for MYO:

  • Moat Score: 5
  • GF Value™: $3.13 vs. price of $1.04 (66.8% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the MYO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myomo Business Description

Other Exchanges 0M61:Germany
Address 45 Blue Sky Drive, Suite 101, Burlington, MA, USA, 01803
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
55GF Score

Get the complete analysis for MYO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.04
Price
$3.13
GF Value